An ultimate challenge would be to capture the effect of point mutations on the interaction affinity, e.g., for predicting the outcome of mutation studies or designing specificity changing mutations.
The unequal usage of synonymous codons, often termed as codon usage bias (CUB), is generally thought to be an intricate combined outcome of mutation pressure, natural selection, and genetic drift [ 1- 5].
Population sub-structuring introduces biases in the outcome of mutation-drift equilibrium tests, and therefore the latter must be applied exclusively to panmictic, Wright-Fisher populations (although some tests are robust to population structure).
As a more extreme example, NOMID, one of the most severe autoinflammatory diseases, is one outcome of mutations in NLRP3, an inflammasome-initiating protein modulated by POP2 [ 12, 25].
ABS-Scan provides a user-friendly web interface and will be very much useful for experimentalists to assess the outcome of mutations designed to study protein-ligand (small molecule) interactions.
The cell state into which mutations are introduced is of crucial importance; for example, the tissue and developmental origins of the cell (Li et al., 2005) and its position in the cellular hierarchy (e.g. somatic stem cell, committed progenitor, mature cell) (Bonnet and Dick, 1997) are among the many factors that affect the outcome of mutations.
In Sect. 4, we use a continuous approximation to analyze further the outcome of mutations in a single generation and show that one generation is already enough for genome size to be bounded, independently from the initial sizes of the genomes.
In conclusion, women's cancer risk perceptions 5 years after disclosure of their BRCA1/2 status depend on decisions about preventive interventions more than simply on the outcomes of mutation tests.
The main outcome of the mutation analysis is the mutation score, which indicates the effectiveness of a test suite.
Finally, our systematic approaches of structure-based analysis for single-point mutations in MxA protein are widely applicable to the evaluation of outcomes of mutations in different types of cancer for those proteins with available structural information.
However, the pathological outcomes of mutations in other pairs do not appear to overlap (i.e. DARS2-mtT-DNAAsp, FARS2-mtT-DNAPhe, MARS2-mtT-DNAMet and SARS2-mtT-DNASer).
